CGEM241220P30000
- 0.00
- 0.000.00%
Cullinan Therapeutics Newsroom
Cullinan Therapeutics Announces Q3 2024 Progress and Outlook
We're Not Very Worried About Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Rate
Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36
JonesTrading Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $34
Leerink Partners Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28
Express News | Cullinan Therapeutics Inc : Jonestrading Raises Target Price to $34 From $29
Cullinan Therapeutics: Promising Developments and Strategic Growth in Autoimmune Therapies
Morgan Stanley Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $38
TD Cowen Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating
Express News | Cullinan Therapeutics Inc Q3 Shr View $-0.81 -- LSEG IBES Data
Cullinan Therapeutics | 10-Q: Q3 2024 Earnings Report
Cullinan Therapeutics 3Q Loss $40.6M >CGEM
Cullinan Therapeutics | 8-K: Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Express News | Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Express News | Cullinan Oncology Q3 Cash & Investments USD 639 Million
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus
Cullinan Oncology Initiated at Buy by UBS
UBS Initiates Cullinan Therapeutics(CGEM.US) With Buy Rating, Announces Target Price $30